FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2921283965> ?p ?o ?g. }

• W2921283965 endingPage "S58" @default.
• W2921283965 startingPage "S50" @default.
• W2921283965 abstract "Typhoid fever is an acute infection characterized by prolonged fever following the ingestion and subsequent invasion of Salmonella enterica serovar Typhi (S. Typhi), a human-restricted pathogen. The incidence of typhoid fever has been most reported in children 5–15 years of age, but is increasingly recognized in children younger than 5 years old. There has been a recent expansion of multidrug-resistant typhoid fever globally. Prior typhoid vaccines were not suitable for use in the youngest children in countries with a high burden of disease. This study aims to determine the efficacy of a typhoid conjugate vaccine (TCV) that was recently prequalified by the World Health Organization, by testing it in children 9 months through 12 years of age in Blantyre, Malawi. In this Phase III, individually randomized, controlled, double-blind trial of the clinical efficacy of TCV, 28 000 children 9 months through 12 years of age will be enrolled and randomized in a 1:1 ratio to receive either Vi-TCV or a meningococcal serogroup A conjugate vaccine. A subset of 600 of these children will be further enrolled in an immunogenicity and reactogenicity sub-study to evaluate the safety profile and immune response elicited by Vi-TCV. Recruiting began in February 2018. All children will be under passive surveillance for at least 2 years to determine the primary outcome, which is blood culture–confirmed S. Typhi illness. Children enrolled in the immunogenicity and reactogenicity sub-study will have blood drawn before vaccination and at 2 timepoints after vaccination to measure their immune response to vaccination. They will also be followed actively for adverse events and serious adverse events. The introduction of a single-dose, efficacious typhoid vaccine into countries with high burden of disease or significant antimicrobial resistance could have a dramatic impact, protecting children from infection and reducing antimicrobial usage and associated health inequity in the world’s poorest places. This trial, the first of a TCV in Africa, seeks to demonstrate the impact and programmatic use of TCVs within an endemic setting. NCT03299426." @default.
• W2921283965 created "2019-03-22" @default.
• W2921283965 creator A5008582602 @default.
• W2921283965 creator A5015444709 @default.
• W2921283965 creator A5015590965 @default.
• W2921283965 creator A5018146103 @default.
• W2921283965 creator A5025149327 @default.
• W2921283965 creator A5028133425 @default.
• W2921283965 creator A5034013271 @default.
• W2921283965 creator A5036782148 @default.
• W2921283965 creator A5037307507 @default.
• W2921283965 creator A5039890048 @default.
• W2921283965 creator A5041683451 @default.
• W2921283965 creator A5051550648 @default.
• W2921283965 creator A5055641523 @default.
• W2921283965 creator A5060283208 @default.
• W2921283965 creator A5071606984 @default.
• W2921283965 creator A5082657535 @default.
• W2921283965 creator A5089239945 @default.
• W2921283965 date "2019-03-07" @default.
• W2921283965 modified "2023-09-27" @default.
• W2921283965 title "Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi" @default.
• W2921283965 cites W1930900408 @default.
• W2921283965 cites W1964049648 @default.
• W2921283965 cites W1998020486 @default.
• W2921283965 cites W2046418337 @default.
• W2921283965 cites W2047498924 @default.
• W2921283965 cites W2049532298 @default.
• W2921283965 cites W2062896113 @default.
• W2921283965 cites W2099903218 @default.
• W2921283965 cites W2102898060 @default.
• W2921283965 cites W2114213575 @default.
• W2921283965 cites W2123999602 @default.
• W2921283965 cites W2126147255 @default.
• W2921283965 cites W2139462981 @default.
• W2921283965 cites W2142999073 @default.
• W2921283965 cites W2335033694 @default.
• W2921283965 cites W2340127586 @default.
• W2921283965 cites W2522677904 @default.
• W2921283965 cites W2559763874 @default.
• W2921283965 cites W2570940652 @default.
• W2921283965 cites W2587454028 @default.
• W2921283965 cites W2593353559 @default.
• W2921283965 cites W2616147260 @default.
• W2921283965 cites W2732320847 @default.
• W2921283965 cites W2748706728 @default.
• W2921283965 cites W2754744488 @default.
• W2921283965 cites W2759562520 @default.
• W2921283965 cites W2788800189 @default.
• W2921283965 cites W2811391733 @default.
• W2921283965 cites W2942290778 @default.
• W2921283965 cites W4243637892 @default.
• W2921283965 cites W4250873783 @default.
• W2921283965 cites W4299811586 @default.
• W2921283965 doi "https://doi.org/10.1093/cid/ciy1103" @default.
• W2921283965 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6405268" @default.
• W2921283965 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30845320" @default.
• W2921283965 hasPublicationYear "2019" @default.
• W2921283965 type Work @default.
• W2921283965 sameAs 2921283965 @default.
• W2921283965 citedByCount "25" @default.
• W2921283965 countsByYear W29212839652019 @default.
• W2921283965 countsByYear W29212839652020 @default.
• W2921283965 countsByYear W29212839652021 @default.
• W2921283965 countsByYear W29212839652022 @default.
• W2921283965 countsByYear W29212839652023 @default.
• W2921283965 crossrefType "journal-article" @default.
• W2921283965 hasAuthorship W2921283965A5008582602 @default.
• W2921283965 hasAuthorship W2921283965A5015444709 @default.
• W2921283965 hasAuthorship W2921283965A5015590965 @default.
• W2921283965 hasAuthorship W2921283965A5018146103 @default.
• W2921283965 hasAuthorship W2921283965A5025149327 @default.
• W2921283965 hasAuthorship W2921283965A5028133425 @default.
• W2921283965 hasAuthorship W2921283965A5034013271 @default.
• W2921283965 hasAuthorship W2921283965A5036782148 @default.
• W2921283965 hasAuthorship W2921283965A5037307507 @default.
• W2921283965 hasAuthorship W2921283965A5039890048 @default.
• W2921283965 hasAuthorship W2921283965A5041683451 @default.
• W2921283965 hasAuthorship W2921283965A5051550648 @default.
• W2921283965 hasAuthorship W2921283965A5055641523 @default.
• W2921283965 hasAuthorship W2921283965A5060283208 @default.
• W2921283965 hasAuthorship W2921283965A5071606984 @default.
• W2921283965 hasAuthorship W2921283965A5082657535 @default.
• W2921283965 hasAuthorship W2921283965A5089239945 @default.
• W2921283965 hasBestOaLocation W29212839651 @default.
• W2921283965 hasConcept C104317684 @default.
• W2921283965 hasConcept C126322002 @default.
• W2921283965 hasConcept C159047783 @default.
• W2921283965 hasConcept C168563851 @default.
• W2921283965 hasConcept C185592680 @default.
• W2921283965 hasConcept C187212893 @default.
• W2921283965 hasConcept C203014093 @default.
• W2921283965 hasConcept C22070199 @default.
• W2921283965 hasConcept C2776714567 @default.
• W2921283965 hasConcept C2777704310 @default.
• W2921283965 hasConcept C2779583294 @default.
• W2921283965 hasConcept C2780868878 @default.
• W2921283965 hasConcept C2994552716 @default.

• next